Cargando…
BSCI-12. Inhibition of melanoma brain metastasis by targeting miR-146a
BACKGROUND: Melanoma has the highest propensity of any cancer to metastasize to the brain, with late-stage patients developing brain metastasis (MBM) in 40% of cases. Survival of patients with MBM is around 8 months with current therapies, illustrating the need for new treatments. MBM development is...
Autores principales: | Wang, Jiwei, Rigg, Emma, Lunavat, Taral R, Zhou, Wenjing, Feng, Zichao, Hoang, Tuyen, Bjerkvig, Rolf, Thorsen, Frits |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351179/ http://dx.doi.org/10.1093/noajnl/vdab071.011 |
Ejemplares similares
-
Inhibition of extracellular vesicle‐derived miR‐146a‐5p decreases progression of melanoma brain metastasis via Notch pathway dysregulation in astrocytes
por: Rigg, Emma, et al.
Publicado: (2023) -
BSCI-19. Therapeutic intervention of lung-, breast-, and melanoma-brain metastasis
por: Kieliszek, Agata, et al.
Publicado: (2021) -
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
por: Nymark Aasen, Synnøve, et al.
Publicado: (2019) -
BSCI-11. Targeting PI3K/Akt/mTOR pathway to prevent melanoma brain metastasis
por: Tehranian, Cedric, et al.
Publicado: (2021) -
BSCI-01. Small RNAseq analysis of microRNAs in brain metastasis
por: Jancalek, Radim, et al.
Publicado: (2021)